WO2002055022A3 - Active metabolite of antifungal compound - Google Patents

Active metabolite of antifungal compound Download PDF

Info

Publication number
WO2002055022A3
WO2002055022A3 PCT/US2002/000160 US0200160W WO02055022A3 WO 2002055022 A3 WO2002055022 A3 WO 2002055022A3 US 0200160 W US0200160 W US 0200160W WO 02055022 A3 WO02055022 A3 WO 02055022A3
Authority
WO
WIPO (PCT)
Prior art keywords
active metabolite
antifungal compound
compound
treating
formula
Prior art date
Application number
PCT/US2002/000160
Other languages
French (fr)
Other versions
WO2002055022A2 (en
Inventor
James F Dropinski
Patricia Scott Hicks
Original Assignee
Merck & Co Inc
James F Dropinski
Patricia Scott Hicks
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc, James F Dropinski, Patricia Scott Hicks filed Critical Merck & Co Inc
Priority to CA002433652A priority Critical patent/CA2433652A1/en
Priority to EP02708948A priority patent/EP1351701A2/en
Priority to JP2002555759A priority patent/JP2004521102A/en
Publication of WO2002055022A2 publication Critical patent/WO2002055022A2/en
Publication of WO2002055022A3 publication Critical patent/WO2002055022A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This invention relates to a method for treating a fungal infection comprising administering to a mammalian subject in need of such treatment, an effective amount of a compound of Formula I or its pharmaceutically acceptable salt, Other aspects of the invention include a method of treating a fungal infection using a combination of the compound of Formula I and a second antifungal agent and pharmaceutical compositions of said combinations.
PCT/US2002/000160 2001-01-09 2002-01-04 Active metabolite of antifungal compound WO2002055022A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002433652A CA2433652A1 (en) 2001-01-09 2002-01-04 Active metabolite of antifungal compound
EP02708948A EP1351701A2 (en) 2001-01-09 2002-01-04 Active metabolite of antifungal compound
JP2002555759A JP2004521102A (en) 2001-01-09 2002-01-04 Active metabolites of antifungal compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26060301P 2001-01-09 2001-01-09
US60/260,603 2001-01-09

Publications (2)

Publication Number Publication Date
WO2002055022A2 WO2002055022A2 (en) 2002-07-18
WO2002055022A3 true WO2002055022A3 (en) 2003-02-27

Family

ID=22989835

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000160 WO2002055022A2 (en) 2001-01-09 2002-01-04 Active metabolite of antifungal compound

Country Status (4)

Country Link
EP (1) EP1351701A2 (en)
JP (1) JP2004521102A (en)
CA (1) CA2433652A1 (en)
WO (1) WO2002055022A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006182672A (en) * 2004-12-27 2006-07-13 Meiji Seika Kaisha Ltd Novel antifungal substance, its manufacturing method and medicinal composition
EP1785432A1 (en) * 2005-11-15 2007-05-16 Sandoz AG Process and intermediates for the synthesis of caspofungin.
CN102488886B (en) * 2011-09-26 2014-03-26 上海天伟生物制药有限公司 Caspofungin preparation with low impurity content and preparation method and application thereof
FR2986970A1 (en) * 2012-02-17 2013-08-23 Agronomique Inst Nat Rech ANTI-OOMYCTIC ACTIVITY OF LIPOPOLYSACCHARIDES (LPS) -BINDING PROTEINS / BACTERICIDAL / PERMEABILITY-INCREASING PROTEINS
EP2948145A1 (en) 2013-01-28 2015-12-02 Pola Pharma Inc. Pharmaceutical composition for diseases caused by pathogenic microorganisms such as aspergillus
WO2014185542A1 (en) 2013-05-17 2014-11-20 Pola Pharma Inc. Pharmaceutical composition for treating vaginitis or pneumonia
CN105481952B (en) * 2014-12-24 2020-12-29 上海天伟生物制药有限公司 Composition containing nitrogen heterocyclic hexapeptide precursor and preparation method and application thereof
CN113564057B (en) * 2021-08-17 2023-06-20 湖北省农业科学院植保土肥研究所 Detoxification antibacterial biocontrol bacterium and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219985A (en) * 1990-10-31 1993-06-15 Merck & Co., Inc. Antifungal agent

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5219985A (en) * 1990-10-31 1993-06-15 Merck & Co., Inc. Antifungal agent

Also Published As

Publication number Publication date
JP2004521102A (en) 2004-07-15
CA2433652A1 (en) 2002-07-18
WO2002055022A2 (en) 2002-07-18
EP1351701A2 (en) 2003-10-15

Similar Documents

Publication Publication Date Title
WO2005030753A3 (en) Therapeutic agents useful for treating pain
WO2002019969A3 (en) (5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
CA2427227A1 (en) Lactam compound
WO2003004098A8 (en) Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
WO2004005286A3 (en) Viral inhibitors
EP1172105A4 (en) Antifungal compositions
WO2005056524A3 (en) Therapeutic agents useful for treating pain
BR0212042A (en) Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound
WO2004018419A3 (en) Benzimidazole quinolinones and uses thereof
WO2002053187A3 (en) Methods and transdermal compositions for pain relief
WO2002080890A3 (en) A jasmonate pharmaceutical composition for treatment of cancer
WO2002070438A3 (en) Compositions for delivering bisphosphonates
WO2007112000A3 (en) Treatment of pain
WO2002076472A3 (en) Pharmaceutical combinations for the treatment of cancer comprising dioxolane nucleoside analogs
WO2005030766A8 (en) Phenyl - carboxamide compounds useful for treating pain
WO2003045306A3 (en) Phenoxy amine compounds and compositions for delivering active agents
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
TW200639159A (en) Treatment of pain
WO2005034883A3 (en) A method of healing skin wounds in mammals and a composition therefor
EP2308479A3 (en) Compounds and compositions for delivering active agents
CA2378613A1 (en) Selective iglur5 receptor antagonists for the treatment of migraine
WO2002015959A3 (en) Compounds and compositions for delivering active agents
WO2002000166A3 (en) New compounds useful as antibacterial agents
WO2002055022A3 (en) Active metabolite of antifungal compound
WO2001066551A8 (en) Azole compounds as therapeutic agents for fungal infections

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2002243462

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2002708948

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2002555759

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2433652

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2002708948

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2002708948

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642